For this purpose, we have developed our ABCR® technology platform.
Based on this we are developing solutions that revolutionize intraoperative blood transfusion and open new possibilities for immunosuppressed patients.
We envision a future where blood transfusions are not only safer but also more precise and patient-focused.
In October 2026 we are proud to launch our CE certification certified medical product CATUVAB®.
With our ABCR Technology platform, we are developing solutions that revolutionize intraoperative blood transfusion and open new possibilities for immunosuppressed patients.
We envision a future where blood transfusions are not only safer and patient-focused.
Since our foundation in 2018, we have been dedicated to reducing the risks and limitations of traditional blood transfusions.
In November 2026 we are proud to launch our CE certification certified medical product CATUVAB®.
With our ABCR Technology platform, we are developing solutions that revolutionize intraoperative blood transfusion and open new possibilities for immunosuppressed patients.
We envision a future where blood transfusions are not only safer and patient-focused.
Since our foundation in 2018, we have been dedicated to reducing the risks and limitations of traditional blood transfusions.
In November 2026 we are proud to launch our CE certification certified medical product CATUVAB®.
Lindis Bloodcare was founded in 2018 by the experienced biotech entrepreneurs Dr. Franzpeter Bracht and Dr. Horst Lindhofer, who are also leading the company today.
In addition, we have a team of dedicated and experienced professionals in all departments of LBC.
Lindis Bloodcare is priviliged to have an accomplished board of experts as advisors for our research and development programs.
Neil Blumberg, MD, is Professor of the Department of Pathology and Laboratory Medicine at the University of Rochester Medical Center and Director of the Transfusion Medicine Unit, Blood Bank, and Stem Cell Storage Facility.
Dr. Ulrich Granzer, PhD, CEO Granzer Regulatory Consultants, Munich, Germany, has been operating a leading consultancy for regulatory affairs and clinical development in Munich since 2002.
Professor Hartmut Link, MD, PhD, Professor of Medicine, is Managing Director of Onkodin GmbH, which develops and publishes digitized oncology treatment regimes, he works also in his Private Practice for Internal Medicine, Hematology & Oncology Kaiserslautern.
Professor Aryeh Shander, MD, FCCM, FCCP, FASA, is Clinical Professor of Anesthesiology, Medicine and Surgery at Icahn School of Medicine at Mount Sinai; Chief of Department of Anesthesiology, Critical Care Medicine, …
